Metarrestin: A New Drug Targeting Cancer Metastasis
Author Information
Author(s): Kashyap Vivek K., Sharma Bhuvnesh P., Pandey Divya, Singh Ajay K., Peasah-Darkwah Godwin, Singh Bhupesh, Roy Kuldeep K., Yallapu Murali M., Chauhan Subhash C.
Primary Institution: University of Texas Rio Grande Valley
Hypothesis
Metarrestin selectively targets the perinucleolar compartment (PNC) to inhibit cancer metastasis.
Conclusion
Metarrestin shows promise as a first-in-class drug that can disrupt the PNC and inhibit cancer metastasis.
Supporting Evidence
- Metarrestin effectively disrupts PNCs in cancer cell lines at submicromolar concentrations.
- Preclinical studies show that metarrestin blocks metastatic development and significantly prolongs survival in mouse models.
- Metarrestin has a favorable pharmacokinetic profile with over 80% oral bioavailability.
Takeaway
Metarrestin is a new medicine that helps stop cancer cells from spreading by targeting a special part of the cell called the perinucleolar compartment.
Methodology
The review summarizes studies on metarrestin's effects on various cancers, including in vitro, in vivo, and human clinical trials.
Limitations
The review does not provide specific quantitative data or detailed clinical trial results.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website